Alerta

Bioerodible cross-linked hydrogel implants and related methods of use

Resumen de: AU2025203519A1

The present disclosure is directed to a composite implant for the sustained release of a therapeutic agent from a hydrogel matrix. The hydrogel matrix may be a cross-linked bioerodible polyethylene glycol (PEG) hydrogel with a therapeutic complex dispersed within the cross-linked bioerodible PEG hydrogel. The therapeutic complex may include a therapeutic agent in association with mesoporous silica particles. The composite implant is configured to be delivered to or implanted into an eye of a subject or patient. The composite implant may be used treat ocular disease in a subject or patient. Ocular diseases may be selected from at least one of neovascular age related macular degeneration (AMD), diabetic macular edema, or macular edema following retinal vein occlusion.

Continuous glucose monitoring device

Resumen de: AU2025203521A1

The present disclosure provides a continuous glucose monitoring device. The continuous glucose monitoring device comprises a body attachable unit configured to attach to a body; an applicator accommodating the body attachable unit, the applicator configured to guide the body attachable unit to be mounted on the body based on manipulation of a user; a housing comprising an inner case and an outer case; a plunger body movably disposed in the housing and configured to move from a first position to a second position along an insertion direction; a needle unit coupled to the plunger body; and a rotatable body being rotated based on a movement of the plunger body. The rotatable body is rotated when the plunger body moves from the first position to the second position. The rotatable body is positioned between the inner case and the plunger body to block movement of the plunger body in a withdrawal direction opposite to the insertion direction when the plunger body reaches the second position.

SYSTEMS AND METHODS FOR PREDICTING FRACTURE RISK USING CIRCULATING F2-ISOPROSTANES

Resumen de: WO2025117940A1

Blood plasma samples are obtained from type 2 diabetes (T2D) patients and a concentration of F2-isoprostanes (F2I) in the sample is quantified. Plasma F2I levels assess oxidative stress levels in the patient and indicate elevated risk of T2D-associated complications including incident clinical fracture, cardiovascular complications, renal disease, etc. in the T2D cohort, independently of other risk factors. Fracture risk in the T2D population is heightened for a given bone mineral density (BMD) and is underestimated by evaluation tools such as Fracture Risk Assessment Tool (FRAX). The patient's BMD T-score can be adjusted based on F2I concentrations, capturing reductions in bone quality as well as quantity that lead to the elevated fracture risk in T2D patients. These diagnostic procedures can be effectively deployed in a patient's course of treatment merely by supplementing an existing blood panel, rather than with a separate blood draw.

WRIST-WORN DEVICE FOR NON-INVASIVELY CHECKING A PERSON'S BLOOD GLUCOSE CONCENTRATION

Resumen de: WO2025116761A1

The invention relates to medicine and technology, and more particularly to non-invasively detecting a change in a person's blood glucose concentration, and can be used in the creation of wrist-worn devices for this purpose, as well as in the creation of socially-oriented systems for the early diagnosis of diabetes and associated diseases in the form of wrist-worn devices. The aim of the invention is to improve the operational efficiency of a wrist-worn device for non-invasively checking a person's blood glucose concentration by reducing the preparation and configuration time required. The technical result of the invention is that of reducing preparation and configuration time and, in general, reducing the time taken to perform a non-invasive check of a person's blood glucose concentration by preventing a mobile unit from moving with or along a wrist strap in relation to the radial artery of a person's arm when the person is walking or using the arm on which the device is worn.

SENSOR FOR WRIST-WORN DEVICE FOR NON-INVASIVELY CHECKING A PERSON'S BLOOD GLUCOSE CONCENTRATION

Resumen de: WO2025116766A1

The invention relates to medicine and technology, and more particularly to non-invasively detecting a change in a person's blood glucose concentration, and can be used in the creation of sensors for non-invasively checking a person's blood glucose concentration. The aim of the invention is to improve the operational efficiency of a sensor for a wrist-worn device for non-invasively checking a person's blood glucose concentration by reducing the preparation and configuration time required. The technical results of the invention include: increasing the adhesive force between a rim and the arm of a person by increasing the contact area between said rim and a wet or dry surface of the arm; reducing the energy spent on non-invasively checking a person's blood glucose concentration; and increasing the heat transfer of the sensor via the crest of the rim to the person's arm by increasing the contact area between the rim and the arm.

SYSTEMS AND METHODS FOR DIABETES MANAGEMENT

Resumen de: AU2023312740A1

Systems, devices and methods are provided for incorporating a medication delivery device into an integrated management system. The integrated management system may be an integrated diabetes management system and may include a glucose monitor, a connected insulin pen, and software. The integrated management system may produce a plurality of reports that may include data related to analyte levels (e.g., glucose levels) and medication delivered (e.g., insulin delivered). The medication delivery device may also provide feedback to the user.

Virtual health coach for facilitating dynamic dosage titration

Resumen de: US12318218B1

A computer-implemented method improves efficacy of diabetes self-management to obtain a measurement message and/or contextual activity information used to determine a suitable insulin dosage to treat a patient. The method includes simulating a health coach in a natural conversation to obtain a measurement of the patient's blood-glucose level, processing the measured blood-glucose level with a personalized insulin titration algorithm to determine an insulin dosage recommendation, and generating an electronic signal configured to cause a corresponding action to be performed by a computing device.

SENSOR MONITORING SYSTEM FOR IN-DWELLING CATHETER BASED TREATMENTS

Resumen de: MX2025005370A

A patient monitoring system may be used with catheters to monitor the infusion and drainage of any solution into the human body. The system may be used, for example, with in-dwelling catheters for peritoneal dialysis in end stage renal disease (ESRD) patients, urinary tract catheters, insulin pumps in diabetic patients, feeding tubes and central venous line catheters. The patient monitoring system includes one or more fluid pathways for infusing into and/or draining solutions out of the catheter, and one or more sensors to monitor the fluid. The patient monitoring system transmits the patient monitoring data to a database, allowing data storage, processing, and access through graphical user interfaces to patients and providers via device applications or browser-based web access portals.

Pressing type peripheral blood sugar blood collection alternating tool

Resumen de: CN222917534U

The utility model relates to the technical field of blood glucose sampling, in particular to a pressing type peripheral blood glucose sampling alternating tool. According to the technical scheme, the blood sampling plate comprises a plate body and further comprises a left hand model identifier and a right hand model identifier which are fixedly installed on the two sides of the top of the plate body, fixing plates are fixedly installed on the two sides of the top of the plate body, and a plurality of blood sampling position pressing keys are arranged on the left hand model identifier and the right hand model identifier corresponding to each finger. The device is protected in a covering mode, dust accumulation and falling are prevented from affecting use of the device, and repeated blood sampling at a needle inserting point of the same finger part is avoided.

NON-ENZYMATIC ELECTROCHEMICAL GLUCOSE SENSOR AND RELATED FABRICATION PROCESS

Resumen de: WO2025109398A1

Non-enzymatic electrochemical glucose sensor (100), for the detection of glucose in biological fluids, characterized in comprising: - a support (101), having a first surface and a second surface opposite to the first surface; - a first metallic electrode (102a), a second metallic electrode (102b), and a third metallic electrode (102c) deposited on said support (101); - a sensitive element consisting of a compound, having a nanoporous structure, deposited on a surface of the second metallic electrode (102b). The invention is also related to a fabrication process of the non-enzymatic electrochemical glucose sensor (100).

Personalized treatment tool

Resumen de: AU2025203433A1

Personalized treatment tool Abstract The present invention relates to a computer-implemented method for aiding in the guidance of diabetes drug therapy of an individual suffering from diabetes mellitus. The method is based on glucose data from said individual that are received at a processing unit, wherein said glucose data comprise at least three fasting glucose measurement values from said in 10 dividual, and/or at least three matched pre-prandial glucose measurement values and post prandial glucose measurement values at the same meal from said individual. Further con templated by the present invention is a device for aiding in the guidance of drug diabetes therapy of an individual suffering from diabetes, said device comprising a processing unit, and a computer program including computer-executable instructions, wherein said instruc 15 tions, when executed by the processing unit, causes the processing unit to perform the com puter-implemented method of the present invention.

ADAPTIVE DELIVERY PROFILES FOR AUTOMATED INSULIN DELIVERY TREATMENT SYSTEM

Resumen de: US2025170330A1

Disclosed herein are systems and methods for closed loop and/or partial and/or hybrid closed loop therapy that can provide adaptive personal profiles for when glucose levels are not available and/or unreliable from a continuous glucose monitor (CGM), such as, for example, during a warmup period of the CGM sensor. The profile can include temporary delivery profile such as a CGM warmup profile that is activated specifically for the particular scenario and is designed to minimize the risk of blood glucose fluctuations until the glucose levels are available and reliable, such as when the CGM sensor is warmup up and closed loop therapy based on the sensor can be activated.

RETROSPECTIVE RETROFITTING METHOD TO GENERATE A CONTINUOUS GLUCOSE CONCENTRATION PROFILE BY EXPLOITING CONTINUOUS GLUCOSE MONITORING SENSOR DATA AND BLOOD GLUCOSE MEASUREMENTS

Resumen de: US2025169764A1

Continuous Glucose Monitoring (CGM) devices provide glucose concentration measurements in the subcutaneous tissue with limited accuracy and precision. Therefore, CGM readings cannot be incorporated in a straightforward manner in outcome metrics of clinical trials e.g. aimed to assess new glycemic-regulation therapies. To define those outcome metrics, frequent Blood Glucose (BG) reference measurements are still needed, with consequent relevant difficulties in outpatient settings. Here we propose a “retrofitting” algorithm that produces a quasi continuous time BG profile by simultaneously exploiting the high accuracy of available BG references (possibly very sparsely collected) and the high temporal resolution of CGM data (usually noisy and affected by significant bias). The inputs of the algorithm are: a CGM time series; some reference BG measurements; a model of blood to interstitial glucose kinetics; and a model of the deterioration in time of sensor accuracy, together with (if available) a priori information (e.g. probabilistic distribution) on the parameters of the model. The algorithm first checks for the presence of possible artifacts or outliers on both CGM datastream and BG references, and then rescales the CGM time series by exploiting a retrospective calibration approach based on a regularized deconvolution method subject to the constraint of returning a profile laying within the confidence interval of the reference BG measurements. As output, the retrofitting al

Portable Analyte Testing System

Resumen de: US2025169720A1

A biological test system has receptacles for a variety of removable electro-mechanical biological blood test-based elements having multiple features such as lancets or strips. Testing is through an analysis biological test processor that provides results to a user test output with all designed to be contained in a pocket-transportable user biological test form factor that houses all elements. Biological test elements can be interchanged for multiple sensing modalities with automatic activation based on cartridge insertion of a glucose test element, an A1C test element, a ketone test element, or the like. Designs can include a user sampler configuration selector for a user sampling selection that may be analyzed so a user-personalizable, biological sampler control processor can automatically disable operation for test safety if a user sampling selection is determined to be unacceptable. The system can also provide a user cartridge action prompt, a user reselection prompt, or other action to clear the disable.

SENSOR FOR DETECTING GLUCOSE AND LACTATE AND METHODS FOR DETERMINING AEROBIC AND ANAEROBIC THRESHOLDS

Resumen de: US2025169728A1

The present disclosure describes lactate-responsive sensors, sensing systems incorporating a lactate-responsive sensor, and methods of use thereof that would be beneficial for continuously monitoring lactate levels and determining lactate thresholds (both aerobic and anaerobic thresholds). The present disclosure also relates to an analyte sensor for continuously detecting glucose and lactate levels.

COMPRESSION EVENT DETECTION FOR CONTINUOUS GLUCOSE MONITORS

Resumen de: US2025169769A1

A continuous analyte monitoring system includes first and second analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller Is coupled to the analyte sensors and configured evaluate first samples of outputs of the first analyte sensor and second samples of outputs of the second analyte sensor with respect to one another to determine whether the first samples and the second samples indicate compression of the tissue. If the first samples and the second samples indicate compression of the tissue, compensate for the compression of the tissue with respect to the first samples. The controller may evaluate the machine learning models using a machine learning model or a filter.

SYSTEM FOR AUTOMATICALLY PRESCRIBING AND/OR ADJUSTING INSULIN DOSES FOR A PATIENT

Resumen de: US2025174328A1

A system for prescribing insulin doses is provided, wherein a first titration application component structured to is implemented on a patient computing device of the patient, wherein the first titration application component logs glucose level data measured from the patient and insulin dose data indicative of a number of insulin doses given to the patient. The system includes a provider computing including a second titration application component, wherein the second titration application component is structured and configured to receive the glucose level data and the insulin dose data from the patient computing device, determine a correction factor based on a sensitivity constant specified by the healthcare provider, and determine the insulin dose recommendation for the patient based on the insulin dose data, the glucose level data and the correction factor, wherein the provider computing device is structured and configured to transmit the insulin dose recommendation to the patient computing device.

SACCHARIDE SENSING SYSTEMS

Resumen de: US2025172566A1

The present invention relates to saccharide sensing systems including macrocyclic compounds which are capable of binding to a target saccharide (e.g. glucose) and a detectable reporter for providing a detectable signal based on the binding of the target saccharide by the macrocyclic compound.

METHOD AND APPARATUS FOR PROVIDING DATA PROCESSING AND CONTROL IN A MEDICAL COMMUNICATION SYSTEM

Resumen de: US2025172539A1

Techniques for data processing and control for a glucose monitoring system are provided, including obtaining a first sensitivity of a glucose sensor; obtaining a second sensitivity of the glucose sensor; comparing a difference between the first sensitivity and the second sensitivity to a predetermined range of values; if the difference is outside the predetermined range of the values, causing a calibration routine for the glucose sensor to be performed; and if the difference is within the predetermined range of values determining a composite sensitivity for a current calibration of the glucose sensor based on the first sensitivity and the second sensitivity and calculating the glucose level based on the current calibration of the glucose sensor.

System and method for wireless communication of glucose data

Resumen de: AU2025203317A1

Systems, devices, and methods are disclosed for wireless communication of analyte data. One such method includes, during a first interval, establishing a first connection between an analyte sensor system and a display device. During the first connection, the method includes exchanging information related to authentication between the analyte sensor system and the display device. The method includes making a determination regarding whether authentication was performed during the first interval. During a second interval, the method may include establishing a second connection between the analyte sensor system and the display device for transmission of an encrypted analyte value, and bypassing the exchanging of information related to authentication performed during the first connection. The method also includes, during the second interval, the analyte sensor system transmitting the encrypted analyte value to the display device, if the determination indicates that the authentication was performed during the first interval.

Diabetes management partner interface for wireless communication of analyte data

Resumen de: AU2025203318A1

Systems, devices, and methods are disclosed for wireless communication of analyte data. In embodiments, a method of using a diabetes management partner interface to configure an analyte sensor system for wireless communication with a plurality of partner devices is provided. The method includes the analyte sensor system receiving authorization to provide one of the partner devices with access to a set of configuration parameters via the diabetes management partner interface. The set of configuration parameters is stored in a memory of the analyte sensor system. The method also includes, responsive to input received from the one partner device via the diabetes management partner interface, the analyte sensor system setting or causing a modification to the set of configuration parameters, according to a system requirement of the one partner device.

GLUCOSE MONITORING ALARM DEVICE AND RELATED FUNCTIONALITY

Nº publicación: US2025169721A1 29/05/2025

Solicitante:

CUSTOM TYPEONE LLC [US]
Custom TypeOne LLC

Resumen de: US2025169721A1

A notification device is provided for presenting blood glucose level information for a tracked individual. The notification device is configured to receive first and second blood glucose level information from first and second tracking devices associated with different manufacturers. The first and second blood glucose level information each include at least one of a blood glucose level or a first or second derivative for the blood glucose level as a function of time. The notification device comprises a screen, processor(s), and memory device(s) containing computer readable code. When executed by the processor(s), the computer readable code is configured to cause the processor(s) to receive the first and/or the second blood glucose level information and cause presentation of the first and/or the second blood glucose level information on the screen. The first and second tracking devices are each a continuous blood glucose monitor.